Novo Nordisk CEO Mike Doustdar pledged to accelerate research and development and pursue bolt-on acquisitions to rebuild the company's drug pipeline [1].
The move comes as investors express concern over the long-term robustness of the company's product offerings, signaling that financial forecasts alone may not be enough to sustain market confidence.
Speaking at an investor briefing in Copenhagen, Doustdar addressed the gap between Novo Nordisk and its competitors [1]. The CEO said the company can future-proof its operations through a more aggressive approach to innovation and strategic purchases [2].
This strategic shift follows a period of volatility where an upgraded outlook for 2026 failed to lift investor sentiment [1]. The market's reaction suggests a growing worry that the current pipeline lacks the depth required to maintain the company's dominant position in the pharmaceutical landscape [2].
Doustdar said the company would focus on speeding up the R&D process to bring new treatments to market more efficiently [1]. By combining internal research with targeted acquisitions, the company aims to diversify its portfolio, and reduce reliance on a few key blockbuster drugs [2].
The briefing highlighted a perceived gap in competitiveness compared to rivals like Eli Lilly [1]. To close this gap, the company is pivoting toward a model that prioritizes agility in drug development and the integration of smaller, specialized firms to bolster its scientific capabilities [1].
“Novo Nordisk CEO Mike Doustdar pledged to accelerate research and development.”
Novo Nordisk's pivot toward 'bolt-on' acquisitions and accelerated R&D indicates a shift from organic growth to a more aggressive inorganic strategy. This suggests that the company views its current internal pipeline as insufficient to fend off competition from rivals like Eli Lilly, making the acquisition of external biotech assets a necessity for long-term survival in the weight-loss and diabetes markets.
